• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cubist Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Cubist Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1448670
  • December 2010
  • 73 pages
  • Global Markets Direct

Cubist Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Cubist Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cubist Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cubist Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Cubist Pharmaceuticals, Inc. Snapshot
Cubist Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Cubist Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Cubist Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Pipeline Products Glance
Cubist Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Drug Profiles
CB-183,315
Product Description
Mechanism of Action
R&D Progress
CXA-101
Product Description
Mechanism of Action
R&D Progress
CB-182,804
Product Description
Mechanism of Action
R&D Progress
CXA-101 + Tazobactam
Product Description
Mechanism of Action
R&D Progress
ALN-RSV
Product Description
Mechanism of Action
R&D Progress
CB-183,872
Product Description
Mechanism of Action
R&D Progress
Cubist Pharmaceuticals, Inc. – Pipeline Analysis
Cubist Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Cubist Pharmaceuticals, Inc. Pipeline Products By Target
Cubist Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Cubist Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Cubist Pharmaceuticals, Inc. - Dormant Projects
Cubist Pharmaceuticals, Inc. – Company Statement
Cubist Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN
Jun 30, 2010: Cubist Initiates Phase II Study Of CXA-201 For Complicated Intra-Abdominal Infections
Jun 29, 2010: Cubist Announces All Objectives Met In Phase II CXA-101 Complicated Urinary Tract Infections Study
Apr 08, 2010: Cubist Enrolls First Subject In Phase II Trial For Therapy To Treat Clostridium Difficile-Associated Diarrhea
Apr 08, 2010: Cubist Enrolls First Subject In Phase II Trial For Therapy To Treat Clostridium Difficile-Associated Diarrhea
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics
Sep 15, 2009: Calixa Therapeutics To Make Multiple Presentations On CXA-101 And CXA-101/Tazobactam At The 49th Annual Interscience Conference On Antimicrobial Agents And Chemotherapy
Mar 27, 2009: Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
Mar 24, 2009: Calixa Therapeutics Announces Positive Phase I Results For CXA-101, A Novel Intravenous Cephalosporin Antibiotic With Excellent Anti-Pseudomonal Activity
Financial Deals Landscape
Cubist Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Cubist Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Cubist Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Cubist Pharmaceuticals, Inc. Detailed Deal Summary
Asset Purchase
Cubist Pharmaceuticals Acquires 2% Royalty Stream Of CUBICIN From Eli Lilly
Acquisition
Cubist Pharmaceuticals Acquires Calixa Therapeutics
Cubist Pharmaceuticals Acquires Illumigen Biosciences
China Shoto Acquires An Additional 21% Stake In Full Three Dimension Power Engineering
Venture Financing
FORMA Therapeutics Secures Additional $3 Million In Series B Financing Round
Equity Offering
China Shoto Completes Offering For $9.3 Million
Cubist Pharmaceuticals Completes Public Offering Of $120 Million
Debt Offering
Cubist Pharmaceuticals Completes Public Offering Of 2.25% Convertible Notes For $350 Million
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Hydra Biosciences
Evotec Enters Into Research Agreement With Cubist Pharmaceuticals
Beactica Enters Into Co-Development Agreement With Cubist Pharmaceuticals
FORMA Therapeutics Enters Into Co-Development Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam
Cubist Pharmaceuticals Enters Into Co-Promotion Agreement With AstraZeneca
deCODE biostructures Enters Into Research Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Marketing Agreement With Kuhnil Pharmaceuticals
Licensing Agreements
Cubist Pharmaceuticals Enters Into Licensing Agreement With Dyax
Cubist Pharmaceuticals Enters Into Licensing Agreement With Merck
AstraZeneca Enters Into Licensing Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Licensing Agreement With XTL Biopharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS